571 related articles for article (PubMed ID: 28241139)
41. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.
Bitoun E; Oliver PL; Davies KE
Hum Mol Genet; 2007 Jan; 16(1):92-106. PubMed ID: 17135274
[TBL] [Abstract][Full Text] [Related]
42. Taking MLL through the MudPIT: identification of novel complexes that bring together MLL-fusion proteins and transcription elongation factors.
Fromm G; Adelman K
Mol Cell; 2010 Feb; 37(4):449-50. PubMed ID: 20188661
[TBL] [Abstract][Full Text] [Related]
43. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.
Dobson CL; Warren AJ; Pannell R; Forster A; Lavenir I; Corral J; Smith AJ; Rabbitts TH
EMBO J; 1999 Jul; 18(13):3564-74. PubMed ID: 10393173
[TBL] [Abstract][Full Text] [Related]
44. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
45. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.
Slany RK; Lavau C; Cleary ML
Mol Cell Biol; 1998 Jan; 18(1):122-9. PubMed ID: 9418860
[TBL] [Abstract][Full Text] [Related]
46. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
[TBL] [Abstract][Full Text] [Related]
47. Multifaceted roles of YEATS domain-containing proteins and novel links to neurological diseases.
Yeewa R; Chaiya P; Jantrapirom S; Shotelersuk V; Lo Piccolo L
Cell Mol Life Sci; 2022 Mar; 79(3):183. PubMed ID: 35279775
[TBL] [Abstract][Full Text] [Related]
48. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
[TBL] [Abstract][Full Text] [Related]
49. Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system.
Yokoyama A
Cancer Sci; 2021 Oct; 112(10):3935-3944. PubMed ID: 34251718
[TBL] [Abstract][Full Text] [Related]
50. Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking.
Li X; Li XM; Jiang Y; Liu Z; Cui Y; Fung KY; van der Beelen SHE; Tian G; Wan L; Shi X; Allis CD; Li H; Li Y; Li XD
Nat Chem Biol; 2018 Dec; 14(12):1140-1149. PubMed ID: 30374167
[TBL] [Abstract][Full Text] [Related]
51. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
52. ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
Garrison BS; Rybak AP; Beerman I; Heesters B; Mercier FE; Scadden DT; Bryder D; Baron R; Rossi DJ
Blood; 2017 Aug; 130(5):619-624. PubMed ID: 28615219
[TBL] [Abstract][Full Text] [Related]
53. MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells.
Maethner E; Garcia-Cuellar MP; Breitinger C; Takacova S; Divoky V; Hess JL; Slany RK
Cell Rep; 2013 May; 3(5):1553-66. PubMed ID: 23623499
[TBL] [Abstract][Full Text] [Related]
54. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
55. Mature B-cell acute lymphoblastic leukaemia associated with a rare MLL-FOXO4 fusion gene.
Lim L; Chen KS; Krishnan S; Gole L; Ariffin H
Br J Haematol; 2012 Jun; 157(6):651. PubMed ID: 22429121
[No Abstract] [Full Text] [Related]
56. The super elongation complex (SEC) family in transcriptional control.
Luo Z; Lin C; Shilatifard A
Nat Rev Mol Cell Biol; 2012 Sep; 13(9):543-7. PubMed ID: 22895430
[TBL] [Abstract][Full Text] [Related]
57. Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia.
Prasad R; Yano T; Sorio C; Nakamura T; Rallapalli R; Gu Y; Leshkowitz D; Croce CM; Canaani E
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12160-4. PubMed ID: 8618864
[TBL] [Abstract][Full Text] [Related]
58. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription.
Mak AB; Nixon AM; Moffat J
Cancer Res; 2012 Apr; 72(8):1929-34. PubMed ID: 22337994
[TBL] [Abstract][Full Text] [Related]
59. Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML.
Basilico S; Wang X; Kennedy A; Tzelepis K; Giotopoulos G; Kinston SJ; Quiros PM; Wong K; Adams DJ; Carnevalli LS; Huntly BJP; Vassiliou GS; Calero-Nieto FJ; Göttgens B
Nat Commun; 2020 Mar; 11(1):1407. PubMed ID: 32179751
[TBL] [Abstract][Full Text] [Related]
60. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
